This site is intended only for healthcare professionals resident in the Republic of Ireland
IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:
In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1
Please see Full Prescribing lnformation and Patient lnformation
PALOMA was the ﬁrst clinical trial programme to explore how a CDK4/6 inhibitor could beneﬁt women with HR+/HER2- mBC10
With RCT data,1-6 IBRANCE RWE7-9 can help improve understanding of outcomes in patients with HR+/HER2- mBC and help you to better support your patients
Please note the materials are intended for healthcare professionals to effectively support patient care.
A broad range of women with HR+/HER2- mBC may beneﬁt from IBRANCE combination therapy.1-9 IBRANCE is the first CDK4/6 inhibitor supported by data from clinical trials1-4 and real-world evidence.5-7
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023